Loading company…
StratifiCare develops diagnostic tests to help clinicians assess dengue severity and treatment response.
Founded in 2015 and based in Singapore, StratifiCare Pte. Ltd. develops in-vitro diagnostic tests and devices. StratifiDen assesses the risk of severe dengue, while StratifiREY predicts response to Y90 RE treatment. In October 2021, the company raised SGD 1 million in seed funding from ADB Ventures and Sprout, with individual investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in